SML1651
Iloprost
≥98% (HPLC)
别名:
(E)-(3aS, 4R, 5R, 6aS)-Hexahydro-5-hydroxy-4-[(E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl]-Δ2(1H),Δ-pentalenevaleric acid, Cilaprost, ZK 36374; (5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-ynyl]-2(1H)-pentalenylidene]pentanoic acid
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C22H32O4
CAS号:
分子量:
360.49
MDL號碼:
分類程式碼代碼:
51111800
PubChem物質ID:
NACRES:
NA.77
推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
film
儲存條件
desiccated
顏色
colorless
溶解度
DMSO: 10 mg/mL, clear
儲存溫度
−20°C
SMILES 字串
[H][C@@]12[C@@](C/C(C2)=C/CCCC(O)=O)([H])[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C1
InChI
1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18?,19-,20+,21+/m0/s1
InChI 密鑰
HIFJCPQKFCZDDL-SGSAMSKHSA-N
生化／生理作用
Iloprost is a potent prostacyclin PGI2 analog that binds with equal affinity to human prostacyclin (Prostanoid IP) and prostaglandin EP1 receptors. Iloprost acts as a vasodilator and antihypertensive, and inhibits the ADP, thrombin, and collagen-induced aggregation of human platelets. Iloprost dilates systemic and pulmonary arterial vascular beds and has been used clinically for pulmonary arterial hypertension (PAH), scleroderma, and Raynaud′s syndrome.
Iloprost is used to treat children with PH (pulmonary hypertension) after the surgery to clear CHD (congenital heart disease). In transplant patients, this prostacyclin analogue is used to inhibit renal dysfunction. Iloprost performs various functions like vasodilatation and cytoprotection. It has higher stability than prostacyclin.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Meyler's Side Effects of Endocrine and Metabolic Drugs (2009)
A review of the use of iloprost, a synthetic prostacyclin, in the prevention of radiocontrast nephropathy in patients undergoing coronary angiography and intervention.
Kassis HM, et al.
Clinical Cardiology, 38(8), 492-498 (2015)
Iloprost for children with pulmonary hypertension after surgery to correct congenital heart disease.
Xu Z, et al.
Pediatric Pulmonology, 50(6), 588-595 (2015)
Joseph Castillo et al.
Cancer research, 79(15), 3916-3927 (2019-06-12)
Regulatory T cells (Treg) are immunosuppressive and negatively impact response to cancer immunotherapies. CREB-binding protein (CBP) and p300 are closely related acetyltransferases and transcriptional coactivators. Here, we evaluate the mechanisms by which CBP/p300 regulate Treg differentiation and the consequences of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门